



CEPI



Vaccinopolis
University of Antwerp

Enabling the Evaluation of COVID-19 Vaccines with Correlates of Protection Vaccinopolis University of Antwerp, Belgium February 16 - 17, 2023



Mark Connors, M.D.

Chief, HIV-Specific Immunity Section
Bethesda MD, 20892
NIH/NIAID
10 Center Drive, Rm. 11B07

Tel: +01 301-496-8057

E-mail: mconnors@nih.gov

I have 34 years of experience in studying virus-specific immunity to HIV, RSV, and Influenza virus. I did my fellowship training under Robert Chanock and Brian Murphy examining the immune response to respiratory virus vaccines. As Chief of the HIV-Specific Immunity Section of the Laboratory of Immunoregulation, NIAID, I direct research in understanding the mechanistic basis of an effective humoral and cellular response to HIV. Our laboratory seeks to take the best available examples of immunologic control of HIV or neutralizing antibodies to HIV in nature and systematically dissect the underlying mechanisms of these responses. Most important, our work on the cellular and humoral immune response to HIV has had a major impact on our current understanding of the basis of an effective immune response to HIV and other viruses and has suggested possible routes to use that information in strategies for immunization or immunotherapy. More recently we have used this information to examine the components (replication, route, valency, adjuvants, innate immunity response) of vaccines that contribute to an effective immune response to HIV, influenza virus, or SARS-CoV-2. This work includes basic immunology in humans and experimental animals, and the completion of 4 clinical trials of Ad4 recombinant vaccines for HIV and Influenza virus.

